Results 201 to 210 of about 5,065,448 (337)

Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma

, 2014
Patrick A. Ott, Omid Hamid, Anna C. Pavlick, Harriet M. Kluger, Kevin B. Kim, Peter D. Boasberg, Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, Thomas A. Davis, Mario Sznol, Patrick Hwu   +12 more
openalex   +1 more source

Structural basis of immunosuppression by the therapeutic antibody daclizumab [PDF]

, 2010
Hui Yang, Jianchuan Wang, Jiamu Du, Chen Zhong, Dapeng Zhang, Huaizu Guo, Yajun Guo, Jianping Ding   +7 more
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Age‐Specific Frequencies of Antibodies toEscherichia coliVerocytotoxins (Shiga Toxins) 1 and 2 among Urban and Rural Populations in Southern Ontario [PDF]

, 2003
Mohamed A. Karmali, Mariola Mascarenhas, Martin Petric, Lucie Dutil, Kris Rahn, Kerstin U. Ludwig, Gerald S. Arbus, Pascal Michel, Philip M. Sherman, Jeff Wilson, Roger P. Johnson, James B. Kaper   +11 more
openalex   +1 more source

Efficient cellular and humoral immune response and production of virus-neutralizing antibodies by the Hepatitis B Virus S/preS116-42 antigen

, 2022
Ana‐Maria Pantazica, Mihaela‐Olivia Dobrica, Catalin Lazar, Cristina Scurtu, Cătălin Ţucureanu, Iuliana Caraș, Irina Ionescu, Adriana Costache, Adrian Onu, Jihong Liu Clarke, Crina Stăvaru, Norica Branza‐Nichita   +11 more
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Amyloid-β Oligomer Specificity Mediated by the IgM Isotype – Implications for a Specific Protective Mechanism Exerted by Endogenous Auto-Antibodies

, 2010
Malin Lindhagen‐Persson, Kristoffer Brännström, Monika Vestling, Michael Steinitz, Anders Olofsson   +4 more
openalex   +2 more sources

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source

Development of VHH Antibodies against Dengue Virus Type 2 NS1 and Comparison with Monoclonal Antibodies for Use in Immunological Diagnosis

, 2014
Aneela Fatima, Haiying Wang, Keren Kang, Liliang Xia, Ying Wang, Wei Ye, Jufang Wang, Xiaoning Wang   +7 more
openalex   +2 more sources

Development of monoclonal antibodies specific forRicinusagglutinins [PDF]

, 2009
David L. Brandon, Bradley Hernlem
openalex   +1 more source